[Antiandrogen strategies in prostate cancer: reconstitution of oestrogen receptor beta]
Related Experiment Video
Updated: Jun 10, 2026
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
P Thelen1, A Strauss, M Stettner
1Urologische Universitätsklinik, Georg-August-Universität Göttingen, Robert-Koch-Strasse 40, 37075, Göttingen, Deutschland.
Abstract:
In advanced prostate cancer, albeit castration resistant, an active androgen receptor is still pivotal for growth and cell survival. Recent therapies involving more effective antiandrogens such as MDV3100 proved to be successful. Furthermore, blocking de novo intracrine androgen synthesis, e.g. with abiraterone acetate, provides additional benefit. Besides these antiandrogen measures, compounds which enable the reconstitution of the oestrogen receptor beta as a tumour suppressor restrain aberrant androgen receptor signalling.
Insights
In advanced prostate cancer, even when castration-resistant, targeting the androgen receptor remains crucial. New therapies like MDV3100 and abiraterone acetate, alongside oestrogen receptor beta reconstitution, offer promising strategies to control cancer growth.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Context:
- Advanced prostate cancer often remains dependent on androgen receptor (AR) signaling, even after castration.
- Current treatments include potent antiandrogens (e.g., MDV3100) and inhibitors of androgen synthesis (e.g., abiraterone acetate).
- Aberrant AR signaling drives tumor progression and resistance to therapy.
Purpose:
- To explore therapeutic strategies targeting androgen receptor signaling in castration-resistant prostate cancer.
- To investigate the role of novel antiandrogens and androgen synthesis inhibitors.
- To evaluate the potential of oestrogen receptor beta (ERB) as a tumor suppressor in this context.
Summary:
- Active androgen receptor (AR) drives growth in advanced, castration-resistant prostate cancer.
- Effective therapies include advanced antiandrogens (e.g., MDV3100) and blocking androgen synthesis (e.g., abiraterone acetate).
- Reconstituting oestrogen receptor beta (ERB) can suppress tumors and restrain AR signaling.
Impact:
- These therapeutic approaches offer new avenues for managing advanced prostate cancer.
- Targeting AR signaling and ERB may improve patient outcomes and overcome treatment resistance.
- Understanding these pathways is key to developing more effective prostate cancer therapies.
